Nasdaq nmra.

NMRA Profile. Company Profile. Neumora Therapeutics Inc. 490 Arsenal Way. Suite 200. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ... Ventyx Biosciences, Inc. (NASDAQ:VTYX) fell 22.1% to $23.38 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia and other neuropsychiatric …Neumora Therapeutics (NASDAQ: NMRA) is owned by 23.77% institutional shareholders, 65.44% Neumora Therapeutics insiders, and 10.79% retail investors. Amgen Inc is the largest individual Neumora Therapeutics shareholder, owning 35.37M shares representing 23.16% of the company. Amgen Inc's Neumora Therapeutics shares are currently valued …

Neumora Therapeutics press release (NASDAQ:NMRA): Q3 GAAP EPS of -$1.14 misses by $0.74. $519.5 million in cash, cash equivalents and marketable securities expected to support operations into 2026.Complete Neumora Therapeutics Inc. stock information by Barron's. View real-time NMRA stock price and news, along with industry-best analysis.Neumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...

WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult …Neumora Therapeutics Inc. (NASDAQ:NMRA)’s traded shares stood at 0.14 million during the last session. At the close of trading, the stock’s price was $11.91, to imply an increase of 1.88% or $0.22 in intraday trading. The NMRA share’s 52-week high remains $17.74, putting it -48.95% down since ...

WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug ...Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .Oct 10, 2023 · Shares of Neumora Therapeutics Inc (NASDAQ:NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange.. RBC Capital Markets On Neumora Therapeutics ... 10 Okt 2023 ... Market Conditions: The broader stock market experienced a mixed situation on October 2, 2023. This can be attributed to concerns such as ...Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...

Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.

Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

NMRA | Complete Neumora Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Encontre o valor de abertura e fechamento das cotações NMRA para ficar atualizado sobre as tendências do mercado financeiro. Compartilhe sua visão de mercado, interaja com …Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...The latest price target for Neumora Therapeutics ( NASDAQ: NMRA) was reported by JP Morgan on Tuesday, October 10, 2023. The analyst firm set a price target for 21.00 expecting NMRA to rise to ...1.55. EBIT. -130.9. -237.31. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Neumora Therapeutics, Inc. (NMRA). See many years of revenue, …Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics ( NASDAQ: NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer ...Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ...

Nov 24, 2023 · Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ... VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...Sep 21, 2023 · Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The initiation of this Phase 1 study is an important step in the development of NMRA-266.Nov 1, 2023 · WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ... Nov 27, 2023 · 1.55. EBIT. -130.9. -237.31. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Neumora Therapeutics, Inc. (NMRA). See many years of revenue, expenses and ... In addition, Neumora has granted the underwriters a 30-day option to purchase up to 2,206,500 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on September 15, 2023 under the ticker …

NMRA Neumora Therapeutics, Inc. Stock Price & Overview. Follow 212 followers. $12.250.00 (0.00%)11:37 AM 12/01/23. NASDAQ | $USD | Realtime. Summary · Ratings ...

Download Historical Stock Quotes for Neumora Therapeutics Inc [NASDAQ,NMRA] in a range of formats.NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders.Investors can buy NMRA even cheaper than Gosebruch did, with shares changing hands as low as $10.01 at last check today -- that's 20.7% under Gosebruch's purchase price. VIDEO: Thursday 9/21 ...Neumora Therapeutics press release (NASDAQ:NMRA): Q3 GAAP EPS of -$1.14 misses by $0.74. $519.5 million in cash, cash equivalents and marketable securities expected to support operations into 2026.WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...Neumora Therapeutics. 's revenue in 2023 is N/A.. On average, 1 Wall Street analysts forecast NMRA's revenue for 2026 to be $3,327,405,256, with the lowest NMRA revenue forecast at $3,327,405,256, and the highest NMRA revenue forecast at $3,327,405,256.Sep 28, 2023 · VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...

1 Nov 2023 ... (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for ...

Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...

Nov 27, 2023 · NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ... When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings? A. Neumora Therapeutics ( NMRA) is scheduled to report earnings on February 15, 2024. The last reported earnings were for reported on ... Dec 1, 2023 · View Our Latest Research Report on NMRA. Neumora Therapeutics Price Performance. NASDAQ:NMRA opened at $12.25 on Thursday. The stock has a fifty day simple moving average of $11.42. $8.11 +0.06 +0.75% Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.... (NASDAQ: NMRA), and Syllable Life Sciences (acquired by Neumora). Portfolio. Atalanta Therapeutics. Atalanta Therapeutics is a biotechnology company pioneering ...WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience …Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ...Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ... --Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.D., as executive vice ...Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings? A. Neumora Therapeutics ( NMRA) is scheduled to report earnings on February 15, 2024. The last reported earnings were for reported on ...

Neumora Therapeutics (NASDAQ:NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with an ...Sep 15, 2023 · The Watertown, MA-based Neumora Therapeutics ( NASDAQ: NMRA ), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its ... NMRA | Complete Neumora Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Instagram:https://instagram. biggest losing stocks todayhow to read share chartbest rated stock appbarrons gym NMRA Neumora Therapeutics Inc Form 8-K - Current report false 0001885522 0001885522 2023-11-01 2023-11-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT R...Dec 1, 2023 · View Our Latest Research Report on NMRA. Neumora Therapeutics Price Performance. NASDAQ:NMRA opened at $12.25 on Thursday. The stock has a fifty day simple moving average of $11.42. what half dollars are worthpfizer rsv vaccine mrna Nov 22, 2023 · 6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On average, they predict the company's stock price to reach $22.67 in the next year. This suggests a possible upside of 90.3% from the stock's current price. View live price data for NMRA (Neumora Therapeutics, Inc.) on TrendSpider to track real-time price action, options flow, and news on this asset and hundreds more. Dark Light. Search Ctrl + K. Login Try full version. Smart Watchlists. NMRA. NMRA. Neumora Therapeutics, Inc. 10.02 USD +0.38 (+3.94%) Last updated Oct 13, 21:00 UTC. … property tax increase in california NASDAQ: NMRA · IEX Real-Time Price · USD. Add to Watchlist 11.92 +0.01 (0.08%) Nov 24, 2023, 4:30 PM EST - Market closed. Overview; Financials; ... Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for NMRA stock stock is $22, which predicts an increase of 84.56%. The lowest target is $18 …Download Historical Stock Quotes for Neumora Therapeutics Inc [NASDAQ,NMRA] in a range of formats.